Boehringer Ingelheim plans 3-year, $84M expansion in Mexico

Boehringer Ingelheim's Mexico production sites are slated to be expanded over the next three years. (Boehringer Ingelheim)

Boehringer Ingelheim intends to make a significant investment in its three manufacturing sites in Mexico in the next three years, starting with its site near Mexico City where it makes diabetes meds.   

The drugmaker today said it will invest about 1 billion Mexican pesos ($52 million) over the next two years in its Xochimilco site, a sum that should boost capacity. The goal is to increase production to 2.5 billion tablets annually in 2028 from about 1.6 billion tablets now, the company said, according to a translated story in Milenio. 

RELATED: Boehringer Ingelheim builds $100M facility to launch complex solids

Free Daily Newsletter

Like this story? Subscribe to FiercePharma!

Biopharma is a fast-growing world where big ideas come along daily. Our subscribers rely on FiercePharma as their must-read source for the latest news, analysis and data on drugs and the companies that make them. Sign up today to get pharma news and updates delivered to your inbox and read on the go.

The plant expansion, which will allow the German drugmaker to increase export capacity to the U.S. as well as to Argentina, Colombia and Brazil, was announced by Miguel Salazar, CEO of Boehringer in Mexico, Central America and the Caribbean, according to the report.  

The expansion at the Xochimilco plant is part of an investment plan to invest 1.6 billion pesos ($84 million) by 2023 to boost production at all three of its production sites in the country, Manufacturing Chemist reports.

The expansion in Mexico comes as the company has made some changes in the way it treats newer, more complex products as opposed to older products that are easier to manufacture.   

Last year, Boehringer started construction on a $100 million R&D and manufacturing facility in Germany where it will both develop and manufacture more complex tablets for global launches. At the same time, it is moving production of what it calls “older, easier-to-manufacture drugs” to other sites worldwide.

Suggested Articles

P&G, the packaged goods giant that bought Merck KgAA’s consumer unit, is out in force at Lions Health. Is that a message for rivals?

Jazz Pharma's next drug launch is set for early July after a DEA scheduling for sleepiness drug Sunosi.

AstraZeneca is rolling with a series of trial wins for Calquence in CLL. Will those data help the drug challenge Imbruvica’s blockbuster sales?